Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Antengene Corporation Limited ( (HK:6996) ) just unveiled an update.
Antengene Corporation Limited reported a 36.7% increase in revenue for the year ended December 31, 2024, driven by strong sales in Mainland China, despite a price reduction following the inclusion of XPOVIO® in the National Reimbursement Drug List. The company also achieved substantial cost reductions across research and development, selling and distribution, and administrative expenses, resulting in a decreased annual loss of RMB319.3 million, compared to RMB581.2 million in the previous year. This financial performance highlights Antengene’s improved operational efficiency and strategic market positioning.
More about Antengene Corporation Limited
Antengene Corporation Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative oncology therapies. The company primarily operates in the Asia-Pacific region, with a significant market focus on Mainland China.
YTD Price Performance: 530.0%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €257.3M
For a thorough assessment of 6996 stock, go to TipRanks’ Stock Analysis page.